- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06900348
Prostate Specific Antigen Levels of Individuals Living in Rural Areas
March 28, 2025 updated by: Feyza Bardak, Suleyman Demirel University
Prostate Specific Antigen Levels and Its Relationship With Some Characteristics in Individuals Living in Rural Areas: A Cross-Sectional Study
It was planned in cross-sectional design in order to determine the specific prostate antigen level and some characteristics and the relationship evaluations and prostate specific antigen formation in individuals living in rural areas.
It was planned to perform socio-demographic information formula, form including social information of health, prostate specific antigen test in the project data recording.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
It was planned in a cross-sectional design to evaluate the prostate specific antigen level and its relationship with some characteristics in elderly individuals living in rural areas and to determine the prostate specific antigen level.
The research area of the project consists of 8 villages.
In the collection of project data, it was planned to conduct a socio-demographic feature information form, a form including social determinants of health, and a prostate specific antigen test.
This planned project is the first research to be conducted in our country in terms of determining risky groups, ensuring randomness in participants, and sampling method for universe representation.
In addition, screening the rural area, which is disadvantaged in terms of socio-economic and demographic aspects, and preferring elderly individuals constitute the steps taken to ensure health equality of the disadvantaged group in terms of health service transportation opportunities.
Study Type
Observational
Enrollment (Estimated)
308
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
Male 55 years or older
Description
Inclusion Criteria:
- Male
- 55 years or older
Exclusion Criteria:
-Prostate treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PSA levels
Time Frame: 6 months
|
For ages 60-69: 0 - 4.5 ng/ml, For ages 70 and above: 0 - 6.5 ng/ml
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 25, 2025
Primary Completion (Estimated)
July 30, 2025
Study Completion (Estimated)
August 30, 2025
Study Registration Dates
First Submitted
March 22, 2025
First Submitted That Met QC Criteria
March 22, 2025
First Posted (Actual)
March 28, 2025
Study Record Updates
Last Update Posted (Actual)
March 30, 2025
Last Update Submitted That Met QC Criteria
March 28, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TSTK-2024-9546
- Suleyman Demirel Universty (Registry Identifier: TSTK-2024-9546)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Carcinoma
-
M.D. Anderson Cancer CenterJanssen PharmaceuticaActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Oligometastatic Prostate CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingCastration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Refractory Prostate Carcinoma | Metastatic Castration-Resistant Prostate CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate CancerUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Thomas...Novartis; Prostate Cancer Clinical Trials ConsortiumTerminatedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7 | Prostate Carcinoma Metastatic in the BoneUnited States
-
Mayo ClinicCongressionally Directed Medical Research ProgramsRecruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Locally Advanced Prostate CarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8United States
Clinical Trials on PSA-Activated PSA-PAH1
-
Sophiris Bio CorpCompleted
-
Karolinska InstitutetThe Swedish Research Council; Swedish Cancer FoundationActive, not recruiting
-
St. Joseph's Hospital and Medical Center, PhoenixTerminatedEssential TremorUnited States
-
Case Comprehensive Cancer CenterCompleted
-
London Health Sciences Centre Research Institute...Zimmer BiometRecruiting
-
Canandaigua VA Medical CenterCompleted
-
National Cancer Institute (NCI)CompletedProstate Cancer | Prostate NeoplasmUnited States
-
Al-Hawash Private UniversityEnrolling by invitationthe Detection of Prostate Cancer in MenSyrian Arab Republic
-
Chinese University of Hong KongCompletedAtherosclerosis | Psoriatic Arthritis | Arterial StiffnessChina
-
Heinrich-Heine University, DuesseldorfRecruitingProstate CancerGermany